Innate sensing of malaria parasites

Nature Reviews Immunology

Volumn 14, Issue 11, 2014, Pages 744-757

  Gazzinelli, Ricardo T ^a,b,c   Kalantari, Parisa ^a   Fitzgerald, Katherine A ^a   Golenbock, Douglas T ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CRYOPYRIN; CYTOKINE; DNA; GAMMA INTERFERON; GLYCOSYLPHOSPHATIDYLINOSITOL; INFLAMMASOME; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; PATTERN RECOGNITION RECEPTOR; RNA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; URIC ACID; HEMOPROTEIN; HEMOZOIN; MALARIA VACCINE; PROTOZOAL DNA; PROTOZOAL RNA;

ANEMIA; BRAIN MALARIA; ERYTHROCYTE; HEMOLYSIS; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIFE CYCLE; MALARIA; MEROZOITE; METABOLIC ACIDOSIS; NONHUMAN; PARASITE; PARASITE DEVELOPMENT; PARASITEMIA; PATHOGENESIS; PLACENTA; PLASMODIUM; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SENSOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPOROZOITE; GENETICS; IMMUNOLOGY; MACROPHAGE; MALARIA FALCIPARUM; PARASITOLOGY; PATHOLOGY;

DNA, PROTOZOAN; ERYTHROCYTES; HEMEPROTEINS; HUMANS; IMMUNITY, INNATE; MACROPHAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RNA, PROTOZOAN;

EID: 84922392636     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3742     Document Type: Review

References (165)

1. Murray, C. J. et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379, 413-431 (2012).
2. Gething, P. W. et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl. Trop. Dis. 6, e1814 (2012).
3. Miller, L. H., Ackerman, H. C., Su, X. Z. & Wellems, T. E. Malaria biology and disease pathogenesis: insights for new treatments. Nature Med. 19, 156-167 (2013).
4. Golgi, C. On the cycle of development of malarial parasites in tertian fever: differential diagnosis between the intracellular parasites of tertian and quartant fever. Archivio per le Scienza Mediche 13, 173-196 (Italian) (1889).
5. O'Neill, L. A., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors-redefining innate immunity. Nature Rev. Immunol. 13, 453-460 (2013).
6. Barbalat, R., Ewald, S. E., Mouchess, M. L. & Barton, G. M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185-214 (2011).
7. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
8. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805-820 (2010).
9. Gazzinelli, R. T. & Denkers, E. Y. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nature Rev. Immunol. 6, 895-906 (2006).
10. Schofield, L. & Grau, G. E. Immunological processes in malaria pathogenesis. Nature Rev. Immunol. 5, 722-735 (2005).
11. Clark, I. A., Budd, A. C., Alleva, L. M. & Cowden, W. B. Human malarial disease: a consequence of inflammatory cytokine release. Malar. J. 5, 85 (2006).
12. Del Portillo, H. A. et al. The role of the spleen in malaria. Cell. Microbiol. 14, 343-355 (2012).
13. Buffet, P. A. et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117, 381-392 (2011).
14. Franklin, B. S. et al. MyD88-dependent activation of dendritic cells and CD4+ T lymphocytes mediates symptoms, but is not required for the immunological control of parasites during rodent malaria. Microbes Infect. 9, 881-890 (2007).
15. Franklin, B. S. et al. Malaria primes the innate immune response due to interferon-γ induced enhancement of Toll-like receptor expression and function. Proc. Natl Acad. Sci. USA 106, 5789-5794 (2009).
16. Ataide, M. A. et al. Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection. PLoS Pathog. 10, e1003885 (2014).
17. Cunnington, A. J., Riley, E. M. & Walther, M. Stuck in a rut? Reconsidering the role of parasite sequestration in severe malaria syndromes. Trends Parasitol. 29, 585-592 (2013).
18. Chang, K. H. & Stevenson, M. M. Malarial anaemia: mechanisms and implications of insufficient erythropoiesis during blood-stage malaria. Int. J. Parasitol. 34, 1501-1516 (2004).
19. Awandare, G. A. et al. Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-induced proinflammatory mediators in an in vitro model. Am. J. Hematol. 86, 155-162 (2011).
20. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
21. Tracey, K. J. & Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491-503 (1994).
22. Wagner-Jauregg, J. & Bruetsch, W. L. The history of the malaria treatment of general paralysis. Am. J. Psychiatry 102, 577-582 (1946).
23. Taylor, W. R., Hanson, J., Turner, G. D., White, N. J. & Dondorp, A. M. Respiratory manifestations of malaria. Chest 142, 492-505 (2012).
24. Van den Steen, P. E. et al. Pathogenesis of malaria-associated acute respiratory distress syndrome. Trends Parasitol. 29, 346-358 (2013).
25. White, N. J., Turner, G. D., Day, N. P. & Dondorp, A. M. Lethal malaria: Marchiafava and Bignami were right. J. Infect. Dis. 208, 192-198 (2013).
26. Scherf, A., Lopez-Rubio, J. J. & Riviere, L. Antigenic variation in Plasmodium falciparum. Annu. Rev. Microbiol. 62, 445-470 (2008).
27. Kraemer, S. M. & Smith, J. D. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr. Opin. Microbiol. 9, 374-380 (2006).
28. Shikani, H. J. et al. Cerebral malaria: we have come a long way. Am. J. Pathol. 181, 1484-1492 (2012).
29. Idro, R., Jenkins, N. E. & Newton, C. R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4, 827-840 (2005).
30. Rogerson, S. J., Hviid, L., Duffy, P. E., Leke, R. F. & Taylor, D. W. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect. Dis. 7, 105-117 (2007).
31. Dondorp, A. M. et al. Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J. Infect. Dis. 197, 79-84 (2008).
32. Francischetti, I. M. et al. Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes. J. Thromb. Haemost. 5, 155-165 (2007).
33. Anstey, N. M. et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J. Exp. Med. 184, 557-567 (1996).
34. Ong, P. K. et al. Nitric oxide synthase dysfunction contributes to impaired cerebroarteriolar reactivity in experimental cerebral malaria. PLoS Pathog. 9, e1003444 (2013).
35. Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989).
36. Almeida, I. C. & Gazzinelli, R. T. Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and functional analyses. J. Leukoc. Biol. 70, 467-477 (2001).
37. Krishnegowda, G. et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem. 280, 8606-8616 (2005).
38. Durai, P., Govindaraj, R. G. & Choi, S. Structure and dynamic behavior of Toll-like receptor 2 subfamily triggered by malarial glycosylphosphatidylinositols of Plasmodium falciparum. FEBS J. 280, 6196-6212 (2013).
39. Schofield, L. & Hackett, F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J. Exp. Med. 177, 145-153 (1993).
40. Tachado, S. D. et al. Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway. J. Immunol. 156, 1897-1907 (1996).
41. Schofield, L. et al. Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. J. Immunol. 156, 1886-1896 (1996).
42. Jani, D. et al. HDP-a novel heme detoxification protein from the malaria parasite. PLoS Pathog. 4, e1000053 (2008).
43. Nguyen, P. H., Day, N., Pram, T. D., Ferguson, D. J. & White, N. J. Intraleucocytic malaria pigment and prognosis in severe malaria. Trans. R. Soc. Trop. Med. Hyg. 89, 200-204 (1995).
44. Jaramillo, M. et al. Synthetic Plasmodium-like hemozoin activates the immune response: a morphology-function study. PLoS ONE 4, e6957 (2009).
45. Parroche, P. et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl Acad. Sci. USA 104, 1919-1924 (2007).
46. Shio, M. T. et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog. 5, e1000559 (2009).
47. Dostert, C. et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS ONE 4, e6510 (2009).
48. Coban, C. et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201, 19-25 (2005).
49. Giribaldi, G. et al. Involvement of inflammatory chemokines in survival of human monocytes fed with malarial pigment. Infect. Immun. 78, 4912-4921 (2010).
50. Skorokhod, O. A., Schwarzer, E., Ceretto, M. & Arese, P. Malarial pigment haemozoin, IFN-y, TNF-a, IL-1 p and LPS do not stimulate expression of inducible nitric oxide synthase and production of nitric oxide in immuno-purified human monocytes. Malar. J. 6, 73 (2007).
51. Goldie, P., Roth, E. F Jr., Oppenheim, J. & Vanderberg, J. P. Biochemical characterization of Plasmodium falciparum hemozoin. Am. J. Trop. Med. Hyg. 43, 584-596 (1990).
52. Barrera, V. et al. Host fibrinogen stably bound to hemozoin rapidly activates monocytes via TLR-4 and CD11b/CD18-integrin: a new paradigm of hemozoin action. Blood 117, 5674-5682 (2011).
53. Kalantari, P. et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by Plasmodium-derived hemozoin and DNA during malaria. Cell Rep. 6, 196-210 (2014).
54. Coban, C. et al. Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 7, 50-61 (2010).
55. Torgbor, C. et al. A multifactorial role for P. falciparum malaria in endemic Burkitt's lymphoma pathogenesis. PLoS Pathog. 10, e1004170 (2014).
56. Reimer, T. et al. Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur. J. Immunol. 40, 764-769 (2010).
57. Rock, K. L., Latz, E., Ontiveros, F. & Kono, H. The sterile inflammatory response. Annu. Rev. Immunol. 28, 321-342 (2010).
58. Griffith, J. W., Sun, T., McIntosh, M. T. & Bucala, R. Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J. Immunol. 183, 5208-5220 (2009).
59. Caetano, B. C. et al. Requirement of UNC93B1 reveals a critical role for TLR7 in host resistance to primary infection with Trypanosoma cruzi. J. Immunol. 187, 1903-1911 (2011).
60. Schamber-Reis, B. L. et al. UNC93B1 and nucleic acid-sensing Toll-like receptors mediate host resistance to infection with Leishmania major. J. Biol. Chem. 288, 7127-7136 (2013).
61. Andrade, W. A. et al. Combined action of nucleic acid-sensing Toll-like receptors and TLR11/TLR12 heterodimers imparts resistance to Toxoplasma gondii in mice. Cell Host Microbe 13, 42-53 (2013).
62. Pichyangkul, S. et al. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J. Immunol. 172, 4926-4933 (2004).
63. Wu, X., Gowda, N. M., Kumar, S. & Gowda, D. C. Protein-DNA complex is the exclusive malaria parasite component that activates dendritic cells and triggers innate immune responses. J. Immunol. 184, 4338-4348 (2010).
64. Sharma, S. et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35, 194-207 (2011).
65. Anstey, N. M., Douglas, N. M., Poespoprodjo, J. R. & Price, R. N. Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv. Parasitol. 80, 151-201 (2012).
66. Wu, J. et al. Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. Proc. Natl Acad. Sci. USA 111, E511-E520 (2014).
67. Liehl, P. et al. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nature Med. 20, 47-53 (2014).
68. Baccarella, A., Fontana, M. F., Chen, E. C. & Kim, C. C. Toll-like receptor 7 mediates early innate immune responses to malaria. Infect. Immun. 81, 4431-4442 (2013).
69. Miller, J. L., Sack, B. K., Baldwin, M., Vaughan, A. M. & Kappe, S. H. Interferon-mediated innate immune responses against malaria parasite liver stages. Cell Rep. 7, 436-447 (2014).
70. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
71. Mantel, P. Y. & Marti, M. The role of extracellular vesicles in Plasmodium and other protozoan parasites. Cell. Microbiol. 16, 344-354 (2014).
72. Gallego-Delgado, J., Ty, M., Orengo, J. M., van de Hoef, D. & Rodriguez, A. A surprising role for uric acid: the inflammatory malaria response. Curr. Rheumatol Rep. 16, 401 (2014).
73. Figueiredo, R. T. et al. Characterization of heme as activator of Toll-like receptor 4. J. Biol. Chem. 282, 20221-20229 (2007).
74. Butt, A. N. & Swaminathan, R. Overview of circulating nucleic acids in plasma/serum. Ann. NY Acad. Sci. 1137, 236-242 (2008).
75. Barrat, F. J. & Coffman, R. L. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223, 271-283 (2008).
76. Franklin, B. S. et al. Plasma circulating nucleic acids levels increase according to the morbidity of Plasmodium vivax malaria. PLoS ONE 6, e19842 (2011).
77. Orengo, J. M. et al. Plasmodium-induced inflammation by uric acid. PLoS Pathog. 4, e1000013 (2008).
78. Lopera-Mesa, T. M. et al. Plasma uric acid levels correlate with inflammation and disease severity in Malian children with Plasmodium falciparum malaria. PLoS ONE 7, e46424 (2012).
79. Couper, K. N. et al. Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. PLoS Pathog. 6, e1000744 (2010).
80. Combes, V. et al. Circulating endothelial microparticles in malawian children with severe falciparum malaria complicated with coma. JAMA 291, 2542-2544 (2004).
81. Campos, F. M. et al. Augmented plasma microparticles during acute Plasmodium vivax infection. Malar. J. 9, 327 (2010).
82. Wassmer, S. C., Combes, V., Candal, F. J., Juhan-Vague, I. & Grau, G. E. Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect. Immun. 74, 645-653 (2006).
83. Wagener, F. A. et al. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 55, 551-571 (2003).
84. Pamplona, A. et al. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nature Med. 13, 703-710 (2007).
85. Ferreira, A. et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell 145, 398-409 (2011).
86. Yeo, T. W. et al. Increased carboxyhemoglobin in adult falciparum malaria is associated with disease severity and mortality. J. Infect. Dis. 208, 813-817 (2013).
87. Gozzelino, R. et al. Metabolic adaptation to tissue iron overload confers tolerance to malaria. Cell Host Microbe 12, 693-704 (2012).
88. Riley, E. M. & Stewart, V. A. Immune mechanisms in malaria: new insights in vaccine development. Nature Med. 19, 168-178 (2013).
89. Stevenson, M. M. & Riley, E. M. Innate immunity to malaria. Nature Rev. Immunol. 4, 169-180 (2004).
90. Sexton, A. C. et al. Transcriptional profiling reveals suppressed erythropoiesis, up-regulated glycolysis, and interferon-associated responses in murine malaria. J. Infect. Dis. 189, 1245-1256 (2004).
91. Ockenhouse, C. F. et al. Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. Infect. Immun. 74, 5561-5573 (2006).
92. Bastos, K. R. et al. Impaired macrophage responses may contribute to exacerbation of blood-stage Plasmodium chabaudi chabaudi malaria in interleukin-12-deficient mice. J. Interferon Cytokine Res. 22, 1191-1199 (2002).
93. Artavanis-Tsakonas, K. & Riley, E. M. Innate immune response to malaria: rapid induction of IFN-γ from human NK cells by live Plasmodium falciparum-infected erythrocytes. J. Immunol. 169, 2956-2963 (2002).
94. Walther, M. et al. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J. Immunol. 177, 5736-5745 (2006).
95. Sponaas, A. M. et al. Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood 114, 5522-5531 (2009).
96. Sedegah, M., Finkelman, F. & Hoffman, S. L. Interleukin 12 induction of interferon y-dependent protection against malaria. Proc. Natl Acad. Sci. USA 91, 10700-10702 (1994).
97. Stevenson, M. M., Tam, M. F, Wolf, S. F. & Sher, A. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-yand TNF-a and occurs via a nitric oxide-dependent mechanism. J. Immunol. 155, 2545-2556 (1995).
98. Su, Z. & Stevenson, M. M. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J. Immunol. 168, 1348-1355 (2002).
99. Wykes, M. N. & Good, M. F What really happens to dendritic cells during malaria? Nature Rev. Microbiol. 6, 864-870 (2008).
100. Ing, R., Segura, M., Thawani, N., Tam, M. & Stevenson, M. M. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J. Immunol. 176, 441-450 (2006).
101. Torgler, R. et al. Sporozoite-mediated hepatocyte wounding limits Plasmodium parasite development via MyD88-mediated NF-K B activation and inducible NO synthase expression. J. Immunol. 180, 3990-3999 (2008).
102. Gowda, N. M., Wu, X. & Gowda, D. C. TLR9 and MyD88 are crucial for the development of protective immunity to malaria. J. Immunol. 188, 5073-5085 (2012).
103. Griffith, J. W et al. Toll-like receptor modulation of murine cerebral malaria is dependent on the genetic background of the host. J. Infect. Dis. 196, 1553-1564 (2007).
104. Wykes, M. N. et al. Plasmodium strain determines dendritic cell function essential for survival from malaria. PLoS Pathog. 3, e96 (2007).
105. da Silva, H. B. et al. IFN-y-induced priming maintains long-term strain-transcending immunity against blood-stage Plasmodium chabaudi malaria. J. Immunol. 191, 5160-5169 (2013).
106. Cramer, J. P. et al. MyD88/IL-18-dependent pathways rather than TLRs control early parasitaemia in non-lethal Plasmodium yoelii infection. Microbes Infect. 10, 1259-1265 (2008).
107. Guermonprez, P. et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature Med. 19, 730-738 (2013).
108. Haque, A. et al. Type I interferons suppress CD4+ T-cell-dependent parasite control during blood-stage Plasmodium infection. Eur. J. Immunol. 41, 2688-2698 (2011).
109. Haque, A. et al. Type I IFN signaling in CD8-DCs impairs Th1-dependent malaria immunity. J. Clin. Invest. 124, 2483-2496 (2014).
110. Perry, J. A., Olver, C. S., Burnett, R. C. & Avery, A. C. Cutting edge: the acquisition of TLR tolerance during malaria infection impacts T cell activation. J. Immunol. 174, 5921-5925 (2005).
111. Urban, B. C. et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400, 73-77 (1999).
112. Schwarzer, E., Alessio, M., Ulliers, D. & Arese, P. Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD1 1c in human monocytes. Infect. Immun. 66, 1601-1606 (1998).
113. Pinzon-Charry, A. et al. Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J. Exp. Med. 210, 1635-1646 (2013).
114. Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
115. Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365 (2013).
116. Agnandji, S. T. et al. First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863-1875 (2011).
117. Olotu, A. et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 368, 1111-1120 (2013).
118. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. & Seeberger, P. H. Synthetic GPI as a candidate antitoxic vaccine in a model of malaria. Nature 418, 785-789 (2002).
119. Genton, B. et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185, 820-827 (2002).
120. Thera, M. A. et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004-1013 (2011).
121. King, C. L. et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc. Natl Acad. Sci. USA 105, 8363-8368 (2008).
122. Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337-346 (2009).
123. Onishi, M. et al. Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets. Vaccine 32, 3004-3009 (2014).
124. McCall, M. B. et al. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J. Immunol. 179, 162-171 (2007).
125. Hartgers, F. C. et al. Enhanced Toll-like receptor responsiveness associated with mitogen-activated protein kinase activation in Plasmodium falciparum-infected children. Infect. Immun. 76, 5149-5157 (2008).
126. Leoratti, F. M. et al. Neutrophil paralysis in Plasmodium vivax malaria. PLoS Negl. Trop. Dis. 6, e1710 (2012).
127. Franklin, B. S. et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc. Natl Acad. Sci. USA 108, 3689-3694 (2011).
128. Mabey, D. C., Brown, A. & Greenwood, B. M. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J. Infect. Dis. 155, 1319-1321 (1987).
129. Berkley, J., Mwarumba, S., Bramham, K., Lowe, B. & Marsh, K. Bacteraemia complicating severe malaria in children. Trans. R. Soc. Trop. Med. Hyg. 93, 283-286 (1999).
130. Bronzan, R. N. et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J. Infect. Dis. 195, 895-904 (2007).
131. Were, T. et al. Bacteremia in Kenyan children presenting with malaria. J. Clin. Microbiol. 49, 671-676 (2011).
132. Morpeth, S. C., Ramadhani, H. O. & Crump, J. A. Invasive non-Typhi Salmonella disease in Africa. Clin. Infect. Dis. 49, 606-611 (2009).
133. Scott, J. A. et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 378, 1316-1323 (2011).
134. Cunnington, A. J., de Souza, J. B., Walther, M. & Riley, E. M. Malaria impairs resistance to Salmonella through heme-and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nature Med. 18, 120-127 (2012).
135. Lokken, K. L. et al. Malaria parasite infection compromises control of concurrent systemic non-typhoidal Salmonella infection via IL-10-mediated alteration of myeloid cell function. PLoS Pathog. 10, e1004049 (2014).
136. Cunnington, A. J. et al. Prolonged neutrophil dysfunction after Plasmodium falciparum malaria is related to hemolysis and heme oxygenase-1 induction. J. Immunol. 189, 5336-5346 (2012).
137. Adachi, K. et al. Plasmodium berghei infection in mice induces liver injury by an IL-12-and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol. 167, 5928-5934 (2001).
138. Barboza, R. et al. MyD88 signaling is directly involved in the development of murine placental malaria. Infect. Immun. 82, 830-838 (2014).
139. Coban, C. et al. Pathological role of Toll-like receptor signaling in cerebral malaria. Int. Immunol. 19, 67-79 (2007).
140. Kordes, M., Matuschewski, K. & Hafalla, J. C. Caspase-1 activation of interleukin-1 p (IL-1 p) and IL-18 is dispensable for induction of experimental cerebral malaria. Infect. Immun. 79, 3633-3641 (2011).
141. Grau, G. E. et al. Monoclonal antibody against interferon-ycan prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc. Natl Acad. Sci. USA 86, 5572-5574 (1989).
142. Campanella, G. S. et al. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc. Natl Acad. Sci. USA 105, 4814-4819 (2008).
143. Grau, G. E. et al. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237, 1210-1212 (1987).
144. Kwiatkowski, D. et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q. J. Med. 86, 91-98 (1993).
145. Looareesuwan, S. et al. Pentoxifylline as an ancillary treatment for severe falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 58, 348-353 (1998).
146. Ball, E. A. et al. IFNAR1 controls progression to cerebral malaria in children and CD8+ T cell brain pathology in Plasmodium berghei-infected mice. J. Immunol. 190, 5118-5127 (2013).
147. Palomo, J. et al. Type I interferons contribute to experimental cerebral malaria development in response to sporozoite or blood-stage Plasmodium berghei ANKA. Eur. J. Immunol. 43, 2683-2695 (2013).
148. Vigario, A. M. et al. Recombinant human IFN-a inhibits cerebral malaria and reduces parasite burden in mice. J. Immunol. 178, 6416-6425 (2007).
149. McGuire, W., Hill, A. V., Allsopp, C. E., Greenwood, B. M. & Kwiatkowski, D. Variation in the TNF-a promoter region associated with susceptibility to cerebral malaria. Nature 371, 508-510 (1994).
150. Aucan, C. et al. Interferon-a receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun. 4, 275-282 (2003).
151. Phawong, C. et al. Haplotypes of IL12B promoter polymorphisms condition susceptibility to severe malaria and functional changes in cytokine levels in Thai adults. Immunogenetics 62, 345-356 (2010).
152. Koch, O. et al. IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria. J. Infect. Dis. 185, 1684-1687 (2002).
153. Cabantous, S. et al. Evidence that interferon-γ plays a protective role during cerebral malaria. J. Infect. Dis. 192, 854-860 (2005).
154. Sortica, V. A. et al. IL1B, IL4R, IL12RB1 and TNF gene polymorphisms are associated with Plasmodium vivax malaria in Brazil. Malar. J. 11, 409 (2012).
155. Sabeti, P. et al. CD40L association with protection from severe malaria. Genes Immun. 3, 286-291 (2002).
156. Burgner, D. et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 352, 1193-1194 (1998).
157. Mockenhaupt, F. P. et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc. Natl Acad. Sci. USA 103, 177-182 (2006).
158. Mockenhaupt, F. P. et al. Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J. Infect. Dis. 194, 184-188 (2006).
159. Sam-Agudu, N. A. et al. TLR9 polymorphisms are associated with altered IFN-γ levels in children with cerebral malaria. Am. J. Trop. Med. Hyg. 82, 548-555 (2010).
160. Leoratti, F. M. et al. Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria. J. Infect. Dis. 198, 772-780 (2008).
161. Khor, C. C. et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genet. 39, 523-528 (2007).
162. Shanks, G. D. & White, N. J. The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infect. Dis. 13, 900-906 (2013).
163. Lopes, S. C. et al. Paucity of Plasmodium vivax mature schizonts in peripheral blood is associated with their increased cytoadhesive potential. J. Infect. Dis. 209, 1403-1407 (2014).
164. Mantel, P. Y. et al. Malaria-infected erythrocyte-derived microvesicles mediate cellular communication within the parasite population and with the host immune system. Cell Host Microbe 13, 521-534 (2013).
165. Antonelli, L. R. et al. The CD14+CD16 + inflammatory monocyte subset displays increased mitochondrial activity and effector function during acute Plasmodium vivax malaria. PLoS Pathog. 10, e1004393 (2014).